Table 1.

Patient characteristics and transplantation outcomes

Duration of first CR, mo
Time from diagnosis to transplantation, mo
Disease status before transplantation
Recipient/donor CMV status
Transplantation outcomes
Patient UPN
Age, y
Diagnosis
Preparative regimen
ATG
Chimerism
Disease status
Survival, d
Cause of death
1   59   MDS/RAEB   13   21   1st relapse, untreated   FM180   No   R/R   Donor   CR   1540   NA  
2   61   MDS/RAEB   0   4   Untreated   FM180   No   N/N   ND   Dead   38   Acute GVHD  
3   62   CML   0   109   2nd AP, untreated   FM140*  Yes   N/N   Donor   CR   756   NA  
4   59   AML   6.5   28   1st relapse, untreated   FM180   No   R/R   Donor   CR   1642   NA  
5   59   CML   0   29   Myeloid blast crisis   FM180   No   R/R   NE   Dead   18   Multiorgan failure  
6   60   AML   12.5   25   3rd relapse, untreated   FM180   No   N/R   Donor   Dead   1181   Fungal pneumonia  
7   62   AML   16   19   1st relapse, refractory   FM180   No   N/R   Donor   Dead   92   Acute GVHD  
8   58   AML   8   15   1st relapse, refractory   FM180   No   R/R   Donor   Dead   42   Recurrence of disease  
9   57   CML   0   50   2nd AP, untreated   FM180   No   N/R   ND   Dead   35   Sepsis, pulmonary hemorrhage, renal failure  
10   56   CML   2.5   5   Myeloid blast crisis   FM180   No   N/R   ND   Dead   38   Acute GVHD  
11   56   AML   13.5   19   1st relapse, refractory   FM180   No   R/N   Donor   Dead   72   Acute GVHD  
12   58   CML   0   156   3rd chronic phase   FM140   Yes   N/R   NE   Dead   10   Cardiac failure, subarachnoid hemorrhage  
13   59   CML   0   31   2nd AP, untreated   FB   Yes   N/N   Donor   CR†  361   NA  
14   57   AML   2   11   2nd CR   FM180   No   R/N   Donor   CR   1128   NA  
15   55   CML   0   16   AP, untreated   FM180   Yes   N/R   Donor   CR   1016   NA  
16   64   MDS/RAEB   0   9   Primary induction failure   FM180   Yes   N/R   Donor   CR   872   NA  
17   62   AML   1   20   1st relapse, refractory   FM140   No   N/R   Donor   Dead   92   Acute GVHD  
18   64   AML   12   20   2nd relapse, refractory   FB   Yes   N/N   Donor   Dead   56   Acute GVHD, liver failure  
19   61   MDS   7   17   2nd CR   FM140   Yes   N/N   Donor   CR   910   NA  
20   56   MDS/RAEB   0   7   Primary induction failure   FM140   Yes   N/N   NE   Dead   8   Intracerebral hemorrhage  
21   69   AML   12   21   2nd CR   FB   Yes   N/R   Donor   Dead   217   Chronic GVHD, intracerebral hemorrhage  
22   59   CML   0   18   Chronic phase   FM180   Yes   N/R   Donor   CR   495   NA  
23   55   AML   6   12   2nd CR   FM180   Yes   R/N   Donor   CR   505   NA  
24   64   AML   10   21   1st relapse, refractory   FB   Yes   R/R   Donor   CR   104   NA  
25   56   CML   2.5   15   3rd chronic phase   FM180   Yes   N/R   Donor   CR   336   NA  
26   63   MDS/RAEBt   0   12   Primary induction failure   FM140   Yes   N/N   Donor   Dead   116   Recurrence of disease  
27   55   MDS/RAEB   0   9   Primary induction failure   FM140   Yes   N/N   Donor   Dead   293   Chronic GVHD, Aspergillus pneumonia  
28   68   AML   2.5   8   2nd relapse, untreated   FB   Yes   R/R   Mixed   Dead   58   Persistent disease  
29
 		 55
 		 AML
 		 9
 		 15
 		 1st relapse, refractory
 		 FM140
 		 Yes
 		 R/N
 		 NE
 		 Dead
 		 17
 		 Multiorgan failure, pneumonia
 
Duration of first CR, mo
Time from diagnosis to transplantation, mo
Disease status before transplantation
Recipient/donor CMV status
Transplantation outcomes
Patient UPN
Age, y
Diagnosis
Preparative regimen
ATG
Chimerism
Disease status
Survival, d
Cause of death
1   59   MDS/RAEB   13   21   1st relapse, untreated   FM180   No   R/R   Donor   CR   1540   NA  
2   61   MDS/RAEB   0   4   Untreated   FM180   No   N/N   ND   Dead   38   Acute GVHD  
3   62   CML   0   109   2nd AP, untreated   FM140*  Yes   N/N   Donor   CR   756   NA  
4   59   AML   6.5   28   1st relapse, untreated   FM180   No   R/R   Donor   CR   1642   NA  
5   59   CML   0   29   Myeloid blast crisis   FM180   No   R/R   NE   Dead   18   Multiorgan failure  
6   60   AML   12.5   25   3rd relapse, untreated   FM180   No   N/R   Donor   Dead   1181   Fungal pneumonia  
7   62   AML   16   19   1st relapse, refractory   FM180   No   N/R   Donor   Dead   92   Acute GVHD  
8   58   AML   8   15   1st relapse, refractory   FM180   No   R/R   Donor   Dead   42   Recurrence of disease  
9   57   CML   0   50   2nd AP, untreated   FM180   No   N/R   ND   Dead   35   Sepsis, pulmonary hemorrhage, renal failure  
10   56   CML   2.5   5   Myeloid blast crisis   FM180   No   N/R   ND   Dead   38   Acute GVHD  
11   56   AML   13.5   19   1st relapse, refractory   FM180   No   R/N   Donor   Dead   72   Acute GVHD  
12   58   CML   0   156   3rd chronic phase   FM140   Yes   N/R   NE   Dead   10   Cardiac failure, subarachnoid hemorrhage  
13   59   CML   0   31   2nd AP, untreated   FB   Yes   N/N   Donor   CR†  361   NA  
14   57   AML   2   11   2nd CR   FM180   No   R/N   Donor   CR   1128   NA  
15   55   CML   0   16   AP, untreated   FM180   Yes   N/R   Donor   CR   1016   NA  
16   64   MDS/RAEB   0   9   Primary induction failure   FM180   Yes   N/R   Donor   CR   872   NA  
17   62   AML   1   20   1st relapse, refractory   FM140   No   N/R   Donor   Dead   92   Acute GVHD  
18   64   AML   12   20   2nd relapse, refractory   FB   Yes   N/N   Donor   Dead   56   Acute GVHD, liver failure  
19   61   MDS   7   17   2nd CR   FM140   Yes   N/N   Donor   CR   910   NA  
20   56   MDS/RAEB   0   7   Primary induction failure   FM140   Yes   N/N   NE   Dead   8   Intracerebral hemorrhage  
21   69   AML   12   21   2nd CR   FB   Yes   N/R   Donor   Dead   217   Chronic GVHD, intracerebral hemorrhage  
22   59   CML   0   18   Chronic phase   FM180   Yes   N/R   Donor   CR   495   NA  
23   55   AML   6   12   2nd CR   FM180   Yes   R/N   Donor   CR   505   NA  
24   64   AML   10   21   1st relapse, refractory   FB   Yes   R/R   Donor   CR   104   NA  
25   56   CML   2.5   15   3rd chronic phase   FM180   Yes   N/R   Donor   CR   336   NA  
26   63   MDS/RAEBt   0   12   Primary induction failure   FM140   Yes   N/N   Donor   Dead   116   Recurrence of disease  
27   55   MDS/RAEB   0   9   Primary induction failure   FM140   Yes   N/N   Donor   Dead   293   Chronic GVHD, Aspergillus pneumonia  
28   68   AML   2.5   8   2nd relapse, untreated   FB   Yes   R/R   Mixed   Dead   58   Persistent disease  
29
 		 55
 		 AML
 		 9
 		 15
 		 1st relapse, refractory
 		 FM140
 		 Yes
 		 R/N
 		 NE
 		 Dead
 		 17
 		 Multiorgan failure, pneumonia
 

UPN indicates unique patient number; CR, complete remission; ATG, antithymocyte globulin; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; FM180, fludarabine and 180 mg/m2 melphalan; R, reactive; NA, not applicable; N, nonreactive; ND, not done; CML, chronic myeloid leukemia; AP, accelerated phase; FM140, fludarabine and 140 mg/m2 melphalan; AML, acute myelogenous leukemia; NE, nonevaluable due to early death; FB, fludarabine and busulfan; and RAEBt, refractory anemia with excess blasts in transformation.

*

Received Ara-c in the preparative regimen.

†

Developed cytogenetic relapse on day 215 after transplantation treated with ST1571 (achieved hematologic and cytogenetic complete remission).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal